“Value-based purchasing is built on the premise that audit providers feeding them back information on their performance has been not sufficient,” says Ateev Mehrotra, MD, MPH, associate professor of healthcare policy and medicine at Harvard Medical School and a hospitalist at Beth Israel Deaconess Medical Center. In theory, if a physician were told he or she had performed poorly on a particular measure there would be a reaction and change, but he admits this is not supported by the evidence. For some reason, “audit and feedback” does not make too much of a difference with providers.
Arthur Vercillo, MD, FACS, regional president, Excellus Blue Cross Blue Shield, does not agree that providers were not influenced when presented with value-based practice data. He believes that although they initially resist changing how they practice, “When you look at the behavior later it does change.”
According to Francois de Brantes, MS, MBA, executive director of the Healthcare Incentives Improvement Institute, providing appropriate feedback to providers is now no longer a luxury but a necessity. He cites the example of a group of orthopedic surgeons who were shown their performance data as part of a value-based purchasing program—their basic takeaway was, “All those non—evidence-based things that we knew we shouldn’t do, we finally have a reason not to do.” Mr de Brantes added that many payers have driven incentives against professionalism for decades, “and they are beginning to realize that it may not be a good idea.”
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Use of AI Lets Health System Find Lung Cancer at Early Stages
March 8th 2025Artificial intelligence (AI) helps a Sarasota, Florida, health system catch lung nodules that appear on CT scans for patients treated for scores of conditions, allowing them to be referred for a possible lung cancer diagnosis.
Read More
Shaping Dermatology's Future by Increasing Access, Data, and Advocacy
March 7th 2025Thy N. Huynh, MD, FAAD, Bruce A. Brod, MHCI, MD, FAAD, and Melissa Piliang, MD, FAAD, discussed expanding access to pediatric dermatology, dermatology data aggregation, and advocacy for Medicare physician payment reform, respectively.
Read More